Celgene Licenses Lead Program From Epizyme, Takes Option To Remaining Pipeline

Celgene has expanded its footprint in epigenetics, partnering with histone methyltransferase specialist Epizyme to take immediate rights to its preclinical DOT1L program and a three-year extendable option on the rest of the biotech’s pipeline.